We read with interest the study published by Goldman et al. [@b0005], who identified four patients with diabetic ketoacidosis (DKA) resistant to standard therapy that was triggered by COVID-19 and was associated with high morbidity and mortality. This is also happening in developing countries such as Peru, which has the highest number of COVID-19 cases per million inhabitants and the second-lowest public healthcare spending according to WHO [@b0010].

In our Endocrinology inpatient department at a social security hospital in Peru, from the beginning of the pandemic to date, we have treated 14 patients with DKA who were transferred from the emergency service after they had met the resolution criteria. Of these patients, nine presented with new-onset diabetes. Four tested positive for SARS-CoV-2, three by RT-PCR and one by ELISA, and two patients died. In total, six, six, and two patients had severe, moderate, and mild DKA, respectively. Nine developed acute kidney injury, and six developed acute pancreatitis ([Table 1](#t0005){ref-type="table"} ).Table 1Clinical and biochemical characteristics of patients with diagnosis of diabetic ketoacidosis upon admission.GenderAgeKnown diagnosis of DMSeverity of DKACOVID-19diagnosisAKIpHHCO3^--^\
mmol/LGlucose\
mg/dLAmilase\
U/LLipase\
U/LHbA1c\
% (mmol/mol)Abdominal CT1Male31NoSevereNoYes6.95.688836139617 (162)Edematous pancreas2Male66NoMildNoYes7.2620.5506413242110.9 (96)Edematous pancreas3Male66NoSevereELISANo7.058.67815428412 (108)No abnormalities4Male36NoSevereNoYes6.996.168387147211.4 (101)No abnormalities5Male73YesMildRT-PCRYes7.318.66995131514.3 (133)Hipotrofic pancreas6Male62YesSevereNoYes7.2713.7260600483713.5 (124)Edematous pancreas7Male62YesModerateRT-PCR\*7.314.6121837106\*No abnormalities8Male48NoModerateNoNo7.2311305159100412.9 (117)Diffuse edema of the pancreas9Female36YesSevereRT-PCRYes6.82.54206221515.2 (143)No abnormalities10Male40NoModerateNoNo7.2410.63418914314.6 (136)No abnormalities11Male63NoModerateNoYes7.2511.6104614335312.5 (113)No abnormalities12Male45NoSevereNoYes6.910.510728655818.4 (178)No abnormalities13Male15YesModerateNoYes7.1863764259.5 (80)No abnormalities14Female53NoModerateNoNo71260026416,64710.4 (90)Edematous pancreas[^1][^2][^3]

The mechanism by which SARS-CoV-2 triggers DKA has not been fully elucidated; however, it has been shown that it uses the receptor for angiotensin-converting enzyme 2 as a gateway, which is expressed in the intestine, kidney, and pancreas [@b0015], organs that are part of the "egregious eleven," the pathophysiological basis of type 2 diabetes mellitus [@b0020]. Accordingly, the virus can cause cellular destruction of the islets of Langerhans, which may explain the higher incidence of DKA [@b0015] in patients with and without known diabetes. This damage can be expressed by an elevation of pancreatic enzyme levels in patients with COVID-19 [@b0025]; however, DKA itself can present with elevated pancreatic enzyme levels in 16--25% of cases [@b0030]. Likewise, a state of insulin resistance triggered by COVID-19 has been described, which, together with pancreatic injury, contributes to an increased risk of hyperglycemic crisis in patients with diabetes [@b0015].

In our experience, an insulin infusion pump was continuously used to manage patients with mild and moderate DKA. Hence, healthcare workers were highly exposed to patients with COVID-19. However, the American Diabetes Association and the Joint British Diabetes Societies have recommended the administration of rapid subcutaneous insulin every 4 h [@b0035]. This regimen is safe and effective. Furthermore, it minimizes the time spent for bedside care and conserves the use of personal protective equipment [@b0040], which should be prioritized in our country considering the shortage of equipment, supplies, and medicines needed for COVID-19.

Funding {#s0005}
=======

The authors received no funding from an external source.

Declaration of competing interest
=================================

The authors declare no conflict of interest in this publication.

[^1]: Source: Data obtained from the Endocrinology inpatient department. Guillermo Almenara National Hospital. March-July 2020.

[^2]: \* Not applied: Patient with end stage renal disease.

[^3]: DM: Diabetes mellitus; *DKA:* Diabetic ketoacidosis*;* CT: Computed tomography; *RT-PCR:* Reverse transcription- polymerase chain reaction; AKI: Acute kidney injury; IPT: Insulin pump therapy; HbA1c: Glycated haemoglobin.
